Organovo Holdings (ONVO) Shares are Down -3%

Organovo Holdings (ONVO) : During the past 4 weeks, traders have been relatively bearish on Organovo Holdings (ONVO), hence the stock is down -9.16% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.36% relative to the S&P 500. The 4-week change in the price of the stock is -9.35% and the stock has fallen -3% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 10.53% and the fifty day Moving Average is 2.65%. Organovo Holdings, Inc. is up 38.08% in the last three month period. Year-to-Date the stock performance stands at 55.82%.

Organovo Holdings (ONVO) : Currently there are 2 street experts covering Organovo Holdings (ONVO) stock. The most bullish and bearish price target for the stock is $5 and $5 respectively for the short term. The average price target of all the analysts comes to $4.75. The estimated standard deviation from the target is $0.35.


Organovo Holdings (NYSEMKT:ONVO): On Fridays trading session , Opening price of the stock was $4 with an intraday high of $4. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.8. However, the stock managed to close at $3.88, a loss of 0.51% for the day. On the previous day, the stock had closed at $3.9. The total traded volume of the day was 623,359 shares.

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.